Press Releases

/Press Releases

Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board. Dr. Fleming is Founder and Executive [...]

2020-01-23T08:00:00+00:00 Categories: Press Releases|Tags: |

Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.      Dr. Skyler [...]

2020-01-21T07:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Appoints Dr. Arie Mayer to Board of Directors

Dr. Mayer is the current Managing Director and Chairman of the Board of Merck Life Science Israel NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]

2019-12-05T09:12:00+00:00 Categories: Press Releases|Tags: |

Oramed to Present a Scientific Poster at International Diabetes Federation Congress

NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South [...]

2019-12-02T08:25:00+00:00 Categories: Press Releases|Tags: |

Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and [...]

2019-11-21T08:27:00+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase [...]

2019-11-14T07:28:00+00:00 Categories: Press Releases|Tags: |